| Emerging concepts in the science of vaccine adjuvants B Pulendran, P S. Arunachalam, DT O’Hagan Nature Reviews Drug Discovery 20 (6), 454-475, 2021 | 970 | 2021 |
| Nonviral delivery of self-amplifying RNA vaccines AJ Geall, A Verma, GR Otten, CA Shaw, A Hekele, K Banerjee, Y Cu, ... Proceedings of the National Academy of Sciences 109 (36), 14604-14609, 2012 | 748 | 2012 |
| Advances in vaccine adjuvants M Singh, D O'Hagan Nature biotechnology 17 (11), 1075-1081, 1999 | 711 | 1999 |
| Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome FA Sharp, D Ruane, B Claass, E Creagh, J Harris, P Malyala, M Singh, ... Proceedings of the National Academy of Sciences 106 (3), 870-875, 2009 | 671 | 2009 |
| Cationic microparticles: a potent delivery system for DNA vaccines M Singh, M Briones, G Ott, D O'Hagan Proceedings of the National Academy of Sciences 97 (2), 811-816, 2000 | 629 | 2000 |
| Molecular and cellular signatures of human vaccine adjuvants F Mosca, E Tritto, A Muzzi, E Monaci, F Bagnoli, C Iavarone, D O'Hagan, ... Proceedings of the National Academy of Sciences 105 (30), 10501-10506, 2008 | 615 | 2008 |
| Recent advances in the discovery and delivery of vaccine adjuvants DT O'Hagan, NM Valiante Nature Reviews Drug Discovery 2 (9), 727-735, 2003 | 600 | 2003 |
| The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells A Seubert, E Monaci, M Pizza, DT O’Hagan, A Wack The journal of Immunology 180 (8), 5402-5412, 2008 | 541 | 2008 |
| The mechanism of action of MF59–an innately attractive adjuvant formulation DT O’hagan, GS Ott, E De Gregorio, A Seubert Vaccine 30 (29), 4341-4348, 2012 | 525 | 2012 |
| Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes S Calabro, M Tortoli, BC Baudner, A Pacitto, M Cortese, DT O’Hagan, ... Vaccine 29 (9), 1812-1823, 2011 | 510 | 2011 |
| Recent developments in adjuvants for vaccines against infectious diseases DT O'Hagan, ML MacKichan, M Singh Biomolecular engineering 18 (3), 69-85, 2001 | 472 | 2001 |
| The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent … H Jeffery, SS Davis, DT O'Hagan Pharmaceutical research 10, 362-368, 1993 | 440 | 1993 |
| The history of MF59® adjuvant: a phoenix that arose from the ashes DT O’Hagan, GS Ott, GV Nest, R Rappuoli, GD Giudice Expert review of vaccines 12 (1), 13-30, 2013 | 390 | 2013 |
| Biodegradable microparticles as controlled release antigen delivery systems. DT O'hagan, D Rahman, JP McGee, H Jeffery, MC Davies, P Williams, ... Immunology 73 (2), 239, 1991 | 378 | 1991 |
| A cationic nanoemulsion for the delivery of next-generation RNA vaccines LA Brito, M Chan, CA Shaw, A Hekele, T Carsillo, M Schaefer, J Archer, ... Molecular Therapy 22 (12), 2118-2129, 2014 | 364 | 2014 |
| Recent advances in vaccine adjuvants M Singh, DT O'Hagan Pharmaceutical research 19, 715-728, 2002 | 352 | 2002 |
| Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want H HogenEsch, DT O’Hagan, CB Fox npj Vaccines 3 (1), 51, 2018 | 351 | 2018 |
| The path to a successful vaccine adjuvant–‘the long and winding road’ DT O’Hagan, E De Gregorio Drug discovery today 14 (11-12), 541-551, 2009 | 343 | 2009 |
| Nanoparticles and microparticles as vaccine-delivery systems M Singh, A Chakrapani, D O’Hagan Expert review of vaccines 6 (5), 797-808, 2007 | 334 | 2007 |
| MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection DT O’Hagan Expert review of vaccines 6 (5), 699-710, 2007 | 332 | 2007 |
Manmohan SinghBeam TxEmail verificata su beamtx.com